GlassScriptPhysician profile
Michael J Vargas
NPI 1710926282
$12,687.87
in general payments reported to CMS, 2019-2025
43 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $1,057 · 2021: $1,538 · 2022: $1,934 · 2023: $1,808 · 2024: $2,510 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,389 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,388.87 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,433.08 | 2019-2025 | |
| Cvrx, INC. | $1,093.09 | 2021-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,054.75 | 2019-2025 | Lifevest |
| Abbott Laboratories | $993.03 | 2019-2025 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $930.40 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $795.16 | 2022-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $666.22 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.75 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $620.89 | 2020-2025 | Lokelma, Farxiga |
| Biotronik INC. | $481.51 | 2019-2024 | Amvia Edge |
| Bayer Healthcare Pharmaceuticals INC. | $417.93 | 2019-2025 | |
| Pfizer INC. | $413.46 | 2019-2025 | |
| Novo Nordisk INC | $388.69 | 2021-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $326.78 | 2019-2023 | Watchman Flx, Watchman |
| Esperion Therapeutics, INC. | $193.75 | 2020-2024 | Nexletol |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $179.72 | 2021-2025 | Micra |
| Amgen INC. | $175.85 | 2020-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $171.84 | 2023-2024 | Inpefa |
| Cathworks, INC. | $169.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $161.01 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $155.01 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $143.91 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Arbor Pharmaceuticals, INC. | $127.34 | 2019-2021 | |
| Medtronic Vascular, INC. | $108.40 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $99.63 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $91.99 | 2020-2021 | |
| Bridgebio Pharma, INC. | $87.63 | 2025 | Attruby |
| Lilly USA, LLC | $85.99 | 2022-2025 | Mounjaro, Zepbound |
| Heartflow, INC. | $73.48 | 2022 | |
| Braemar Manufacturing, LLC | $66.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $41.69 | 2019-2020 | |
| Edwards Lifesciences Corporation | $41.22 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $39.90 | 2025 | Shingrix, Arexvy |
| Bardy Diagnostics, INC. | $30.00 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $25.77 | 2023 | Evkeeza |
| Smith+Nephew, INC. | $25.10 | 2023 | Renasys Go V2 Home, Pico |
| Baxter Healthcare | $21.73 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $21.23 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.89 | 2023 | Edarbi |
| Abiomed | $19.79 | 2023 | Impella |
| United Therapeutics Corporation | $18.16 | 2019 | |
| Venclose INC. | $16.40 | 2020 | |
| Allergan, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.